`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`APOTEX CORP.,
`Petitioner
`
`v.
`
`ALCON RESEARCH, LTD.,
`Patent Owner.
`
`Case IPR2013-00428
`U.S. Patent No. 8,268,299
`
`DECLARATION OF ADAM L. PERLMAN IN SUPPORT OF
`MOTION FOR PRO HAC VICE ADMISSION
`PURSUANT TO 37 C.F.R. § 42.10(c)
`
`1.
`
`I, Adam L. Perlman, am more than twenty-one years of age, am
`
`competent to present this declaration, and have personal knowledge of the facts set
`
`forth herein.
`
`2.
`
`This declaration is given in support of the patent owner Alcon
`
`Research, Ltd.'s Motion for/Vo Hac Vice Admission.
`
`3.
`
`I am a member in good standing of the bars of Maryland and the
`
`District of Columbia. I have over fifteen years of patent litigation experience.
`
`1
`
`ALCON 2001
`Apotex Corp. v. Alcon Research, Ltd.
`Case IPR2013-00428
`
`
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`6.
`
`No court or administrative body has ever imposed sanctions or
`
`contempt citations on me.
`
`7.
`
`I have read and will comply with the Office Patent Trial Practice
`
`guide and the Board's Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`8.
`
`I understand that I will be subject to the USPTO Code of Professional
`
`Responsibility set forth in 37 C.F.R. §§ 11.101 et seq. and will be subject to
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`9.
`
`I am concurrently seeking pro hac vice admission in the petitioner's
`
`inter partes challenges to U.S. Patent Nos. 8,323,630 and 8,388,941. Those
`
`proceedings have been designated IPR2013-00429 and IPR2013-00430,
`
`respectively. I have applied to appear pro hac vice in two other proceedings before
`
`the Office in the last three (3) years: (1) Apotex Inc. v. Alcon Pharmaceuticals
`
`Ltd., IPR2013-00012, challenging U.S. Patent No. 6,716,830; and (2) Apotex Inc.
`
`v. Alcon Pharmaceuticals Ltd., IPR2013-00015, challenging U.S. Patent No.
`
`7,671,070, a continuation of the '830 patent.
`
`2
`
`ALCON 2001
`Apotex Corp. v. Alcon Research, Ltd.
`Case IPR2013-00428
`
`
`
`10.
`
`I am familiar with the subject matter at issue in the present
`
`proceeding. I currently represent Alcon in parallel litigation in the U.S. District
`
`Court for the District of Delaware in which the same patent is at issue: Alcon
`
`Research, Ltd. v. Mylan Pharmaceuticals Inc. & Mylan Inc., No. l:13-cv-01332-
`
`SLR; Alcon Research, Ltd. v. Wockhardt Ltd., Wockhardt Bio AG, & Wockhardt
`
`USA, LLC, No. l:13-cv-02040-SLR; and Alcon Research, Ltd. v. Micro Labs Ltd.
`
`& Micro Labs USA Inc., No. l:14-cv-00014-UNA.
`
`11.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true, and further that these statements were made with the
`
`knowledge that willful false statements and the like so made are punishable by fine
`
`or imprisonment, or both, under 18 U.S.C. § 1001.
`
`Adam L. Perlman
`
`3
`
`ALCON 2001
`Apotex Corp. v. Alcon Research, Ltd.
`Case IPR2013-00428